Net profit of Unichem Laboratories reported to Rs 83.99 crore in the quarter ended December 2023 as against net loss of Rs 63.93 crore during the previous quarter ended December 2022. Sales rose 43.60% to Rs 434.38 crore in the quarter ended December 2023 as against Rs 302.50 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales434.38302.50 44 OPM %8.78-14.14 - PBDT43.82-30.50 LP PBT15.96-61.28 LP NP83.99-63.93 LP Powered by Capital Market - Live News

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 5 February 2024.Powered by Capital Market - Live News

Unichem Laboratories has received ANDA approval for its Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Cardura� (Doxazosin) Tablets, 1 mg, 2 mg, 4 mg and 8 mg, of Viatris Specialty, LLC.Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. The product will be commercialized from Unichem`s Goa Plant. Powered by Capital Market - Live News

Net Loss of Unichem Laboratories reported to Rs 24.49 crore in the quarter ended September 2023 as against net loss of Rs 70.67 crore during the previous quarter ended September 2022. Sales rose 26.40% to Rs 415.63 crore in the quarter ended September 2023 as against Rs 328.82 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales415.63328.82 26 OPM %2.11-5.57 - PBDT7.57-13.80 LP PBT-21.88-42.23 48 NP-24.49-70.67 65 Powered by Capital Market - Live News

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 1 November 2023.Powered by Capital Market - Live News